

Theodoros Evrenoglou

✉ tevrenoglou@gmail.com

 [LinkedIn](#)

 [Twitter](#)

 [GitHub](#)

Current role

2022-present **Postdoctoral Research Associate**, Université Paris Cité, Research Center of Epidemiology & Statistics (CRESS-UMR1153), Inserm, France.
Project: Integrating multiple sources of evidence for optimized comparative effectiveness research (OptiCER)

Qualifications

2019–2022 **PhD in Biostatistics**, Université Paris Cité, Research Center of Epidemiology & Statistics (CRESS-UMR1153), Inserm, France,
Thesis: "Dealing with sparse data in network meta-analysis",
Supervisor: Dr. Anna Chaimani.

2017–2019 **MSc in Statistics and Operational Research**, Department of Mathematics, University of Ioannina,
Advisor: Prof. D.Mavridis.

2013–2017 **BSc in Mathematics**, Department of Mathematics, University of Ioannina.

Languages, English (proficient level), French (A2 level), Greek (mother tongue).

Professional Experience

2019-present **Responsible for statistical analysis**, Covid-NMA initiative, <https://covid-nma.com/>, Cochrane, France.

2018-2019 **Research Assistant in Biostatistics**, Evidence Synthesis Methods Team, University of Ioannina, <https://esm.uoi.gr/>, Ioannina, Greece.

2017 **Internship**, Hellenic Statistical Authority.

Fellowships

2019-2022 **Full PhD fellowship**, Université Paris Cité (IdEx Individual Fellow).

Visiting Fellowships

2022 **Visiting fellowship funded by Université Paris Cité**, hosted at MRC Clinical Trials Unit at University College London (UCL), working with Prof Ian R. White on new methods for network meta-analysis with rare events.

Teaching

2022 **3 day course on network meta-analysis**, Biarritz, France,
<https://www.cer-methods.com/2021/12/09/nmacourse/>.

2021 **Université Paris Cité**, Teaching courses in "Advanced meta-analysis" and "Network meta-analysis", Msc. in Public Health in Comparative Effectiveness Research, <http://www.mastercer.com>.

Prizes and Awards

- 2022 **Student award at the 43rd Annual Conference of the International Society for Clinical Biostatistics, Newcastle, England.**
Presentation title: Sharing information across patient subgroups to draw conclusions from sparse treatment networks.

Invited talks

- 2021 **A day with... Statistical Methods Group**, Organized by: Cochrane Methods Group.
Presentation title: Penalized regression in network meta-analysis: a new approach for analyzing networks of interventions with rare events
- 2019 **Clinical Studies from A to Z, Proper Research Practice and Monoclonal Antibodies in Neurology, Athens, Greece**, Organized by: Hellenic Academy of Neuroimmunology.
Presentation title: Effect size measures.

Conference oral presentations

- 2022 **43rd Annual Conference of the International Society for Clinical Biostatistics, Newcastle, England.**
Presentation title: Sharing information across patient subgroups to draw conclusions from sparse treatment networks.
- 2022 **Annual Conference of the Society for Research Synthesis Methodology, Portland, Oregon, USA.**
Presentation title: Sharing information across patient subgroups to draw conclusions from sparse treatment networks.
- 2022 **DAGStat Conference, Hamburg, Germany.**
Presentation title: Network meta-analysis of rare events using penalized likelihood regression.
- 2020 **41st Annual Conference of the International Society for Clinical Biostatistics, Krakow, Poland (virtual).**
Presentation title: Network meta-analysis of rare events using penalized likelihood regression.
- 2019 **32nd Panhellenic Statistics Conference, Ioannina, Greece**, Organized by: Greek Statistical Institute and the Department of Mathematics of the University of Ioannina.
Presentation title: Bias reduction of the maximum likelihood estimator in cases of rare events.

Published software

metaCOVID (<https://covid-nma.com/metacovid/>)

Books chapters

1. Evrenoglou T., Metelli S., Chaimani A. (2021), Introduction to Meta-Analysis. In: Piantadosi S., Meinert C.L. (eds) Principles and Practice of Clinical Trials. Springer, Cham. https://doi.org/10.1007/978-3-319-52677-5_287-1

Published research

1. [Evrenoglou T](#), Boutron, I., Seitidis, G., Ghosn, L. and Chaimani, A. (2023), metaCOVID: A web-application for living meta-analyses of COVID-19 trials. *Res Syn Meth*. Accepted Author Manuscript. doi:<https://doi.org/10.1002/jrsm.1627>
2. [Evrenoglou, T](#), White, IR, Afach, S, Mavridis, D, Chaimani, A. Network meta-analysis of rare events using penalized likelihood regression. *Statistics in Medicine*. 2022; 1- 17. doi:10.1002/sim.9562
3. [Evrenoglou, T](#) (2022), Stratification according to disease severity can better reveal the relative effectiveness of treatments for acne vulgaris. *Br J Dermatol*. <https://doi.org/10.1111/bjd.21849>,
4. Graña C, Ghosn L, [Evrenoglou T](#), Jarde A, Minozzi S, Bergman H et al. Efficacy and safety of COVID-19 vaccines. *Cochrane Database of Systematic Reviews* 2022, Issue 12. Art. No.: CD015477. DOI: 10.1002/14651858.CD015477. Accessed 12 December 2022.
5. Davidson M, Menon S, Chaimani A, [Evrenoglou T](#), Ghosn L, Graña C et al. Interleukin-1 blocking agents for treating COVID-19. *Cochrane Database of Systematic Reviews* 2022, Issue 1. Art. No.: CD015308. DOI: 10.1002/14651858.CD015308
6. Ghosn L, Chaimani A, [Evrenoglou T](#), Davidson M, Graña C, Schmucker C et al. Interleukin-6 blocking agents for treating COVID-19: a living systematic review. *Cochrane Database Syst Rev*. 2021 Mar 18;3:CD013881. doi: 10.1002/14651858.CD013881. PMID: 33734435.
7. Afach S, Chaimani A, [Evrenoglou T](#), Penso L, Brouste E, Sbidian E, Le Cleach L. Meta-analysis results do not reflect the real safety of biologics in psoriasis. *Br J Dermatol*. 2021 Mar;184(3):415-424. doi: 10.1111/bjd.19244. Epub 2020 Jul 16. PMID: 32446286.
8. Siafaka V, Zioga A, [Evrenoglou T](#), Mavridis D, Tsaouri S. Illness perceptions and quality of life in families with child with atopic dermatitis. *Allergol Immunopathol (Madr)*. 2020 Nov-Dec;48(6):603-611. doi: 10.1016/j.aller.2020.03.003. Epub 2020 May 20. PMID: 32446783.
9. Afach S, [Evrenoglou T](#), Oubaya N, Le Cleach L, Sbidian E. Most randomized controlled trials for psoriasis used placebo comparators despite the availability of effective treatments. *J Clin Epidemiol*. 2021 May;133:72-79. doi: 10.1016/j.jclinepi.2021.01.013. Epub 2021 Jan 20. PMID: 33482295.
10. S. Afach, A. Chaimani, [T. Evrenoglou](#), N. Oubaya, L. Le Cleach, É. Sbidian, Utilisation du groupe placebo dans les essais contrôlés randomisés sur le psoriasis, *Annales de Dermatologie et de Vénérologie*, Volume 147, Issue 12, Supplement, 2020, Page A247, ISSN 0151-9638, <https://doi.org/10.1016/j.annder.2020.09.338>

Submitted and working papers

1. [Evrenoglou T](#), Metelli, S., Thomas, J. S., Siafis, S., Turner, R. M., Leucht, S., Chaimani, A (2023), Sharing information across patient subgroups to draw conclusions from sparse treatment networks arXiv preprint [arXiv:2301.09442](https://arxiv.org/abs/2301.09442).

Peer review

Research Synthesis Methods, Evidence-Based Mental Health, *British Journal of Dermatology*

Technical skills

Statistical software R, R-Shiny, rjags, SPSS